Skip to main content

Rosetta Licenses Resolver to University of Washington

NEW YORK, April 18 – Rosetta has licensed its Rosetta Resolver Gene Expression Data Analysis System to the University of Washington, the company said Wednesday.

University of Washington researchers will use the system, which analyzes gene expression, in efforts to study the pathogenesis of disease, the chemical contributions to behavior, and molecular influences on behavior.

"The Rosetta Resolver system offers high quality statistics and comprehensive analysis features to help us take our gene expression research to a higher level," Michael Katze, professor of microbiology at the University of Washington, said in a statement.

Resolver can be used with a variety of microarrays from different manufacturers, including Affymetrix GeneChips and Agilent DNA arrays. Rosetta released version 2.0 of the system last quarter and has granted Agilent Technologies sole distribution rights to it. 

Rosetta’s other licensees for the Resolver include the Harvard Center for Genomic Research, Immunex, Paradigm Genetics, and GlaxoSmithKline. Rosetta has also penned deals to use the technology in collaboration with Abbott Labs, Gemini Genomics, Monsanto, and Sangamo Biosciences.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.